Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Medicine, Hematology, Oncology, Life Sciences, Immunology,
Multiple Myeloma   Teclistamab   BCMA-targeted therapy   Relapsed/Refractory   Clinical Trial  

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Focal Deletions of a Promoter Tether Activate the IRX3 Oncogene in T-Cell Acute Lymphoblastic Leukemia

Medicine, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
T-cell acute lymphoblastic leukemia   FTO gene   IRX3 oncogene   enhancer hijacking   CTCF binding site   noncoding genome   tumor suppressor mechanism  

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...

Selective Targeting of Mutated Calreticulin by the Monoclonal Antibody INCA033989 Inhibits Oncogenic Function of MPN

Medicine, Hematology, Oncology, Life Sciences, Immunology,
mutated calreticulin   monoclonal antibody   myeloproliferative neoplasms   targeted therapy   oncogenic function   INCA033989   hematopoiesis  

Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...

Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited

Medicine, Pediatrics, Hematology, Life Sciences, Immunology, Genetics,
Familial Hemophagocytic Lymphohistiocytosis   Diagnostic Criteria   HLH-2004   Cellular Cytotoxicity Assays   Genetic Diagnosis  

Revisited Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis (FHL) Based on HLH-2004: Updates to Diagnostic Criteria and Development of Multipathway Diagnostic Strategies Introduction Familial hemophagocytic lymphohistiocytosis (FHL) is a severe hyperinflammatory disease characterized by abnormal accumulation of macrophages and l...

JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 Cells: Final Phase 2 Trial Results

Medicine, Hematology, Life Sciences, Immunology,
JAK2/mTOR inhibition   acute GVHD   Th1/Th17 cells   allogeneic hematopoietic cell transplantation   clinical trial   immunosuppression   cell differentiation  

Inhibition of JAK2/mTOR Fails to Effectively Prevent Acute Graft-versus-Host Disease (GVHD): Limitations of Targeting Th1/Th17 Cells In recent years, the role of systemic immunosuppressive therapies in preventing acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (alloHCT) has come under scrutiny. Th1 (T...

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study

Medicine, Pediatrics, Hematology, Oncology, Life Sciences, Immunology,
Daratumumab   Acute Lymphoblastic Leukemia   Lymphoblastic Lymphoma   Pediatric   Relapsed/Refractory   DELPHINUS Study   Chemotherapy  

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...